Maestro Agreement and Precision Study II

NCT ID: NCT02376868

Last Updated: 2022-06-08

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 101 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-05-31
• Study Completion Date: 2015-09-30

Brief Summary

Assess the repeatability and agreement of the Optic Disc Parameters, Retinal Nerve Fiber Layer (RNFL) Thickness, Full Retinal Thickness, and Ganglion Cell Thickness between the Maestro and iVue OCT devices.

Conditions

Normal Healthy Subjects With No Known Ocular Diseases; Glaucomatous Eyes; Eyes With Retinal Diseases

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Normal Eyes

Subjects with no known ocular diseases will be scanned with the iVue and Maestro device

3D OCT-1 Maestro

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

iVue

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

Glaucomatous Eyes

Subjects presenting with different stages of glaucoma will be scanned with the iVue and Maestro device

3D OCT-1 Maestro

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

iVue

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

Eyes with Retinal Diseases

Subjects presenting with Retinal pathological eyes will be scanned on the iVue and Maestro device

3D OCT-1 Maestro

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

iVue

Intervention Type: DEVICE

OCT machines used for diagnostic purposes

Interventions

3D OCT-1 Maestro

OCT machines used for diagnostic purposes

Intervention Type: DEVICE

iVue

OCT machines used for diagnostic purposes

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subjects 18 years of age or older on the date of informed consent

2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent

3. Subjects presenting at the site with normal eyes (eyes without pathology)

4. lOP <=21 mmHg bilaterally

5. BCVA 20/40 or better (each eye)

6. Both eyes must be free of eye disease

1. Subjects 18 years of age or older on the date of informed consent

2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent

3. BCVA 20/40 or better in the study eye

4. Visual field defects consistent with glaucomatous optic nerve damage based on with at least one of the following two findings:

1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;

2. Glaucoma hemi-field test "outside normal limits."

5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:

1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially at the inferior or superior poles with or without disc hemorrhage;

2. Localized abnormalities of the peripapillary retinal nerve fiber layer, especially at the inferior or superior poles; or

3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue

1. Subjects 18 years of age or older on the date of informed consent

2. Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent

3. Subjects presenting at the site with retinal disease

4. lOP<= 21 mmHg in the study eye

5. BCVA 20/400 or better in the study eye

6. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

Exclusion Criteria

1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

2. Subjects unable to tolerate ophthalmic imaging

3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

4. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on manufacturer's recommendation), defined as fixation losses> 20% or false positives> 33%, or false negatives> 33%

5. Visual field defects consistent with glaucomatous optic nerve damage with at least one of the following two findings:

1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;

2. Glaucoma hemi-field test "outside normal limits."

6. Presence of any ocular pathology except for cataract

7. Narrow angle

8. History of leukemia, dementia or multiple sclerosis

9. Concomitant use of hydroxychloroquine and chloroquine

1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

2. Subjects unable to tolerate ophthalmic imaging

3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

4. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as fixation losses> 20% or false positives> 33%, or false negatives > 33% in the study eye

5. Presence of any ocular pathology except glaucoma in the study eye

6. History of leukemia, dementia or multiple sclerosis

7. Concomitant use of hydroxychloroquine and chloroquine

1. Subjects previously enrolled in either the Maestro AP study or the Maestro2 study

2. Subjects unable to tolerate ophthalmic imaging

3. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

4. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g., cornea pathology) in the study eye

5. Narrow angle in the study eye

6. History of leukemia, dementia or multiple sclerosis

7. Concomitant use of hydroxychloroquine and chloroquine

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Topcon Medical Systems, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charles Reisman, MS

Role: STUDY_DIRECTOR

Topcon Corporation

Locations

Western University of Health Sciences

Pomona, California, United States

Countries

United States

Other Identifiers

MaestroAPII

Identifier Type: -

Identifier Source: org_study_id